Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajith Nair

Advanced Heart Failure and Transplant Cardiology Houston, TX Medical Doctor

NPI 1679747950 CMS profile 75862

7200 Cambridge St Fl 10, Houston, TX 77030

Open in the dashboard

General payments

$79,556

488 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,249,434 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Ajith Nair of Houston, TX is reported in the CMS Open Payments database as having received $79,556 across 488 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,249,434 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 83rd percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,127 60
2024 General $13,653 85
2023 General $26,949 80
2022 General $17,277 80
2021 General $9,811 65
2020 General $3,087 49
2019 General $3,652 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajith Nair
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Ajith Nair were reported at $5,127. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Ajith Nair Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $3,652 $863 $224–$4,562 $163
2020 $3,087 $452 $122–$3,992 $114
2021 $9,811 $550 $159–$3,571 $132
2022 $17,277 $729 $221–$4,357 $149
2023 $26,949 $1,002 $309–$5,827 $160
2024 $13,653 $931 $273–$5,204 $164
2025 $5,127 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Actelion Pharmaceuticals US, Inc. $28,160 80 payments
  2. Impulse Dynamics (USA) Inc. $21,469 34 payments
  3. Abbott Laboratories $20,612 130 payments
  4. Abiomed $2,809 14 payments
  5. Medtronic Vascular, Inc. $1,037 9 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $771 29 payments
  7. United Therapeutics Corporation $607 31 payments
  8. CVRx, Inc. $490 6 payments
  9. Merck Sharp & Dohme Corporation $479 25 payments
  10. Amgen Inc. $329 20 payments
  11. Other $2,793 110 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $23,725 8 payments
  2. Honoraria $21,150 11 payments
  3. Food and Beverage $17,438 429 payments
  4. Consulting Fee $11,863 14 payments
  5. Travel and Lodging $5,187 12 payments
  6. Education $194 14 payments
Products named General payments · program years 2019–2025
  1. UPTRAVI $27,855 75 payments
  2. OPSUMIT $27,849 75 payments
  3. Optimizer Cardiovascular $10,778 13 payments
  4. Optimizer Cardiovascular $10,778 13 payments
  5. OPTIMIZER Cardiovascular Device $10,520 18 payments
  6. OPTIMIZER Cardiovascular Device $10,520 18 payments
  7. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $8,037 31 payments
  8. CardioMEMS HF System $6,021 9 payments
  9. Impella $2,617 10 payments
  10. CARDIOMEMS $2,198 30 payments
  11. Other $11,777 319 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

2,535

Median for Internal Medicine: 777

Drug cost

$6,644,210

Median for Internal Medicine: $73,373

Branded share of claims

40.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Opsumit Macitentan Brand 114 $1,425,741
Tyvaso Dpi Treprostinil Brand 50 $1,182,961
Adempas Riociguat Brand 82 $1,084,999
Vyndamax Tafamidis Brand 34 $1,034,788
Uptravi Selexipag Brand 27 $690,429
Orenitram Er Treprostinil Diolamine Brand 25 $316,646
Entresto Sacubitril/Valsartan Brand 164 $187,052
Jardiance Empagliflozin Brand 133 $158,150
Eliquis Apixaban Brand 140 $140,035
Tadalafil Generic 111 $124,821

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$77,724

Medicare's payments for the services billed

Medicare patients

189

Average age 68

Services billed

810

87 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 64%
Chronic kidney disease 58%
Diabetes 54%
Atrial fibrillation 50%
Arthritis 46%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $5,972
$5,972 114 —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $5,950
$5,950 27 —
VYNDAQEL
  • PFIZER INC. $129
$129 — —
WINREVAIR
  • Merck Sharp & Dohme Corporation $74
$74 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $42
  • PFIZER INC. $29
$71 140 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

488 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record